WallStreetZen

NYSE: JNJ
Johnson & Johnson Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

JNJ past earnings growth

How has JNJ's earnings growth performed historically?
Company
16.61%
Industry
22.33%
Market
96.23%
JNJ's earnings have grown slower (4.3% per year) than the US Drug Manufacturers - General industry average (11.67%)
Performance
JNJ's earnings have grown slower (4.3% per year) than the US market average (33.21%)
Performance
JNJ's earnings growth is accelerating - its growth over the last year (16.61%) is above its 5-year compound annual rate (4.3%)
Performance

JNJ past revenue growth

How has JNJ's revenue growth performed historically?
Company
10.79%
Industry
18.11%
Market
42.59%
JNJ's revenue has grown slower (4.7% per year) than the US Drug Manufacturers - General industry average (5.44%)
Performance
JNJ's revenue has grown slower (4.7% per year) than the US market average (19.59%)
Performance
JNJ's revenue growth is accelerating - its growth over the last year (10.79%) is above its 5-year compound annual rate (4.7%)
Performance

JNJ earnings and revenue history

Current Revenue
$89.2B
Current Earnings
$17.8B
Current Profit Margin
19.9%
JNJ's has not demonstrated consistent long-term earnings growth over the past 10 years (58.96%)
Performance

JNJ Return on equity

Current Company
27%
Current Industry
33.2%
Current Market
23.1%
JNJ's Return on Equity (27%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

JNJ Return on assets

Current Company
10.2%
Current Industry
7.3%
JNJ is generating higher Return on Assets (10.2%) than the US Drug Manufacturers - General industry average (7.57%)
Performance

JNJ Return on capital employed

Current Company
14.79%
Current Industry
11.7%
JNJ has gotten more efficient at generating Return on Capital (14.79%) compared to 3 years ago (14.72%)
Performance

Johnson & Johnson Earnings & Revenue FAQ

What were JNJ's earnings last quarter?

On Invalid Date, Johnson & Johnson (NYSE: JNJ) reported Q2 2021 earnings per share (EPS) of $2.38, up 72.46% year over year. Total Johnson & Johnson earnings for the quarter were $6.28 billion. In the same quarter last year, Johnson & Johnson's earnings per share (EPS) was $1.38.

What was JNJ's earnings growth in the past year?

As of Q4 2021, Johnson & Johnson's earnings has grown 16.61% year over year. This is 5.72 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 22.33%. Johnson & Johnson's earnings in the past year totalled $17.77 billion.

What was JNJ's revenue last quarter?

On Invalid Date, Johnson & Johnson (NYSE: JNJ) reported Q2 2021 revenue of $23.31 billion up 27.14% year over year. In the same quarter last year, Johnson & Johnson's revenue was $18.34 billion.

What was JNJ's revenue growth in the past year?

As of Q4 2021, Johnson & Johnson's revenue has grown 10.79% year over year. This is 7.31 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 18.11%. Johnson & Johnson's revenue in the past year totalled $89.19 billion.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.